Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$59.51
-0.1%
$58.46
$42.52
$62.89
$121.61B0.2610.45 million shs6.49 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$418.57
-0.1%
$399.38
$356.28
$555.45
$3.11T1.134.42 million shs22.33 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.92
-0.1%
$26.86
$22.88
$28.75
$147.90B0.3537.77 million shs22.30 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.13%+4.32%+1.14%-1.90%+26.69%
Microsoft Corporation stock logo
MSFT
Microsoft
-0.12%-0.79%-3.31%+5.37%-7.51%
Pfizer Inc. stock logo
PFE
Pfizer
-0.02%+2.41%-3.22%-2.76%+12.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$59.51
-0.1%
$58.46
$42.52
$62.89
$121.61B0.2610.45 million shs6.49 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$418.57
-0.1%
$399.38
$356.28
$555.45
$3.11T1.134.42 million shs22.33 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.92
-0.1%
$26.86
$22.88
$28.75
$147.90B0.3537.77 million shs22.30 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.13%+4.32%+1.14%-1.90%+26.69%
Microsoft Corporation stock logo
MSFT
Microsoft
-0.12%-0.79%-3.31%+5.37%-7.51%
Pfizer Inc. stock logo
PFE
Pfizer
-0.02%+2.41%-3.22%-2.76%+12.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.37
Hold$61.313.04% Upside
Microsoft Corporation stock logo
MSFT
Microsoft
2.85
Moderate Buy$560.8834.00% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.6110.39% Upside

Current Analyst Ratings Breakdown

Latest BMY, MSFT, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingBuy
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingOutperform$575.00
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
UpgradeBuy$485.00
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Lower Price Target$678.00 ➝ $573.00
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingBuy
5/6/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price TargetBuy$595.00 ➝ $680.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/5/2026
Microsoft Corporation stock logo
MSFT
Microsoft
DowngradeMarket Perform
5/5/2026
Microsoft Corporation stock logo
MSFT
Microsoft
UpgradeBuyHold
5/5/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price TargetBuy$730.00 ➝ $870.00
(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.52$8.13 per share7.32$9.84 per share6.05
Microsoft Corporation stock logo
MSFT
Microsoft
$281.72B11.04$18.27 per share22.91$55.78 per share7.50
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.39 per share5.90$15.86 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$3.5616.719.800.1715.01%64.87%13.16%7/30/2026 (Estimated)
Microsoft Corporation stock logo
MSFT
Microsoft
$101.83B$16.8024.9121.701.5139.34%31.94%18.47%7/29/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.799.06N/A11.83%19.44%8.41%8/4/2026 (Estimated)

Latest BMY, MSFT, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion
4/29/2026Q3 2026
Microsoft Corporation stock logo
MSFT
Microsoft
$4.06$4.27+$0.21$4.27$81.44 billion$82.89 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.23%+1.61%70.79%17 Years
Microsoft Corporation stock logo
MSFT
Microsoft
$3.640.87%+10.24%21.67%23 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.64%-13.20%131.30%16 Years

Latest BMY, MSFT, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
3/10/2026
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.910.87%5/21/20265/21/20266/11/2026
3/2/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.23%4/2/20264/2/20265/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.10
1.42
1.28
Microsoft Corporation stock logo
MSFT
Microsoft
0.08
1.28
1.27
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

2 Reasons to Watch PFE and 1 to Stay Cautious
Fed Hawks Now Rule. Will Warsh Go Along with Them?
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$59.50 -0.05 (-0.08%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$59.40 -0.11 (-0.18%)
As of 05/22/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$418.57 -0.52 (-0.12%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$417.78 -0.79 (-0.19%)
As of 05/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

Pfizer stock logo

Pfizer NYSE:PFE

$25.92 -0.03 (-0.12%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$25.91 -0.01 (-0.03%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.